Price
CHART BY
Frequently asked questions
What is Spero's market capitalization?
The market capitalization of Spero is €90.73M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Spero?
Spero's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -€0.832. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Spero's stock?
Currently, 2 analysts cover Spero's stock, with a consensus target price of €3.394. Analyst ratings provide insights into the stock's expected performance.
What is Spero's revenue over the trailing twelve months?
Over the trailing twelve months, Spero reported a revenue of €28.93M.
What is the EBITDA for Spero?
Spero's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -€60.12M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Spero?
Spero has a free cash flow of -€27.44M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Spero have, and what sector and industry does it belong to?
Spero employs approximately 32 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Spero's shares?
The free float of Spero is 38.59M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- €90.73M
- EPS (TTM)
- -€0.832
- Free Float
- 38.59M
- Revenue (TTM)
- €28.93M
- EBITDA (TTM)
- -€60.12M
- Free Cashflow (TTM)
- -€27.44M
Pricing
- 1D span
- €1.60€1.707
- 52W span
- €0.462€2.737
Analyst Ratings
The price target is €3.394 and the stock is covered by 2 analysts.
Buy
0
Hold
2
Sell
0
Information
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
- Employees
- 32
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- SPRO
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet